Barclays’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-100,600
| Closed | -$1.86M | – | 4816 |
|
|
2024
Q1 | $1.86M | Buy |
100,600
+43,600
| +76% | +$1.08M | ﹤0.01% | 2631 |
|
|
2023
Q4 | $1.78M | Buy |
+57,000
| New | +$1.36M | ﹤0.01% | 3004 |
|
|
2023
Q1 | – | Sell |
-50,600
| Closed | -$806K | – | 5058 |
|
|
2022
Q4 | $806K | Buy |
+50,600
| New | +$791K | ﹤0.01% | 2976 |
|
|
2022
Q1 | – | Sell |
-2,500
| Closed | -$58K | – | 4881 |
|
|
2021
Q4 | $58K | Buy |
+2,500
| New | +$50.3K | ﹤0.01% | 3819 |
|
|
2021
Q1 | – | Sell |
-1,900
| Closed | -$102K | – | 4635 |
|
|
2020
Q4 | $102K | Hold |
1,900
| – | – | ﹤0.01% | 4125 |
|
|
2020
Q3 | $78K | Hold |
1,900
| – | – | ﹤0.01% | 4372 |
|
|
2020
Q2 | $92K | Sell |
1,900
-66,500
| -97% | -$3.19M | ﹤0.01% | 4578 |
|
|
2020
Q1 | $2.89M | Sell |
68,400
-303,100
| -82% | -$12.5M | ﹤0.01% | 1934 |
|
|
2019
Q4 | $15.9M | Buy |
371,500
+15,600
| +4% | +$679K | 0.01% | 1081 |
|
|
2019
Q3 | $12.8M | Buy |
355,900
+132,500
| +59% | +$4.02M | 0.01% | 1133 |
|
|
2019
Q2 | $5.97M | Buy |
223,400
+162,500
| +267% | +$4.15M | ﹤0.01% | 1712 |
|
|
2019
Q1 | $1.64M | Sell |
60,900
-36,400
| -37% | -$850K | ﹤0.01% | 2803 |
|
|
2018
Q4 | $1.57M | Buy |
97,300
+7,500
| +8% | +$146K | ﹤0.01% | 2651 |
|
|
2018
Q3 | $1.86M | Buy |
89,800
+15,600
| +21% | +$245K | ﹤0.01% | 2958 |
|
|
2018
Q2 | $1.13M | Sell |
74,200
-21,000
| -22% | -$374K | ﹤0.01% | 3145 |
|
|
2018
Q1 | $2.14M | Sell |
95,200
-8,000
| -8% | -$221K | ﹤0.01% | 2388 |
|
|
2017
Q4 | $3.11M | Sell |
103,200
-23,300
| -18% | -$745K | ﹤0.01% | 2032 |
|
|
2017
Q3 | $4.76M | Buy |
126,500
+42,900
| +51% | +$1.4M | ﹤0.01% | 1568 |
|
|
2017
Q2 | $2.33M | Buy |
83,600
+22,500
| +37% | +$671K | ﹤0.01% | 2111 |
|
|
2017
Q1 | $2.1M | Sell |
61,100
-540,300
| -90% | -$19.1M | ﹤0.01% | 2047 |
|
|
2016
Q4 | $17.3M | Buy |
601,400
+551,200
| +1,098% | +$14.6M | 0.02% | 665 |
|
|
2016
Q3 | $1.6M | Sell |
50,200
-43,700
| -47% | -$1.48M | ﹤0.01% | 2182 |
|
|
2016
Q2 | $3.05M | Sell |
93,900
-405,000
| -81% | -$13.6M | ﹤0.01% | 1678 |
|
|
2016
Q1 | $13.5M | Buy |
498,900
+345,700
| +226% | +$7.54M | 0.02% | 630 |
|
|
2015
Q4 | $5.36M | Buy |
153,200
+75,900
| +98% | +$2.67M | 0.01% | 1267 |
|
|
2015
Q3 | $2.55M | Sell |
77,300
-37,700
| -33% | -$1.57M | ﹤0.01% | 1913 |
|
|
2015
Q2 | $4.71M | Buy |
115,000
+6,200
| +6% | +$240K | 0.01% | 1529 |
|
|
2015
Q1 | $3.48M | Sell |
108,800
-9,100
| -8% | -$313K | ﹤0.01% | 1839 |
|
|
2014
Q4 | $3.65M | Buy |
117,900
+23,700
| +25% | +$672K | ﹤0.01% | 1970 |
|
|
2014
Q3 | $2.26M | Sell |
94,200
-19,600
| -17% | -$458K | ﹤0.01% | 2556 |
|
|
2014
Q2 | $2.5M | Buy |
113,800
+31,400
| +38% | +$656K | ﹤0.01% | 2373 |
|
|
2014
Q1 | $1.98M | Sell |
82,400
-62,100
| -43% | -$1.57M | ﹤0.01% | 2559 |
|
|
2013
Q4 | $3.47M | Sell |
144,500
-73,400
| -34% | -$1.73M | ﹤0.01% | 2124 |
|
|
2013
Q3 | $5.88M | Buy |
217,900
+92,200
| +73% | +$1.93M | 0.01% | 1550 |
|
|
2013
Q2 | $2.28M | Buy |
+125,700
| New | +$1.73M | ﹤0.01% | 2404 |
|
Other funds holding ACAD
BBA
VPM
RI
VCM
PAI
Barclays's ACAD Position: Q1 2026 in Review
Barclays reduced its Acadia Pharmaceuticals (ACAD) stake by 92% in Q1 2026, selling an estimated $8.14M and leaving 27,803 shares worth $619K. The position accounts for ﹤0.01% of the portfolio, ranked #3060.
Barclays first reported a position in ACAD in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.9M in Q3 2019. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.
- Barclays held 27,803 shares of Acadia Pharmaceuticals worth $619K as of Q1 2026.
- Barclays sold 340,501 Acadia Pharmaceuticals shares in Q1 2026, an estimated $8.14M.
- Acadia Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3060 holding.
- Barclays first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's Acadia Pharmaceuticals position peaked at $10.9M in Q3 2019.
- 341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.